Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.

A study of 132 patients with AML given venetoclax-based therapy, 10 profiled by single-cell sequencing, linked immune features to treatment response.

Cancer care demand is constantly shifting, with panelists at PCOC 2026 debating the benefits of automation vs retaining live patient access.

Clinicians at Population Health Roundtables shared obesity care innovations, from pharmacist-led models to same-day liver screening

Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.

Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.